Quellos High Throughput Screening Core
Small Molecule Screening
High throughput screening (HTS) of chemical (small molecule) libraries against cells or classical biochemical targets has been the mainstay of the pharmaceutical industry generating drug leads that can be further optimized for "first-in-man" clinical studies. The Quellos High Throughput Screening Core's Small Molecule Library currently contains more than 115,000 separate chemical entities selected for their "drug-like" behaviors and diverse coverage of the bioactive chemical or pharmacophore space. We are currently offering services for assay development, optimization and a variety of screening programs (e.g., the "Informer Screen", "Secondary" screen and OncoProfSet Profiling) that are directed towards the Quellos High Throughput Screening Core's collections of small molecules.
Chemical Library
The primary portion of our small molecule library was acquired from ChemBridge Corporation. Initially it contains approximately 115,000 separate entities at 10mM concentration in 100% DMSO and stored in 96 well plates (80 compounds per plate, ~1,500 plates). DIVERSet is 50K subset of compounds from the library that corresponds to our "Informer Screen." Secondary Screens will be performed on a subset of the remaining library (>64K compounds) corresponding to ChemBridges' CNS-Set, KINASet and ION Channel Set. Other facility collections will be included in the derivation of the screening subset. We reformat the screening collections into the standard 384 well format in order to improve efficiency and save on screening costs.
Other collections in our library include:
- The NCI Diversity Set #1 that was derived from a Developmental Therapeutics Program (DTP) at the National Cancer Institute, National Institute of Health. The set contains nearly 2,000 entities derived from the original library of 140,000 compounds created by submission from external investigators worldwide or DTP directed syntheses.
- The FDA Approved Oncology Drug Set: Derived from the DTP, this set contains 85+ drugs that are currently approved for cancer chemotherapeutic application. We have formatted this collection to yield sensitivity information via 12 point dose response analysis on clients’ cell lines of interest.
- MicroSource Discovery System’s Spectrum Collection: This is a 2000 compound set made up of known drugs (50% with designations from USP, USAN, INN, BAN and JAN), Natural Products (30%) and other bioactive components (20%). Components of this collection were identified by Vendor-selected medicinal chemists and biologists to offer a wide range of biological activities and structural diversity. Such content provides our clients the opportunity to explore and evaluate drugs and known biochemical tools on systems of their choice.
Contact:
Timothy J. Martins, Ph.D.
Co-Director
Phone: 206-616-3115
E-mail: tmartins@uw.edu
